NCT01107106View on ClinicalTrials.gov

Safety, Tolerability, and Efficacy of ellaOne® (Ulipristal Acetate) for Emergency Contraception in Postmenarcheal Adolescent Girls and Women

CompletedOBSERVATIONAL
Enrollment

579

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

January 31, 2013

Study Completion Date

February 28, 2013

Conditions
Contraception
Interventions
DRUG

ellaOne® (ulipristal acetate)

one single oral dose (30 mg tablet)

DRUG

ellaOne® (ulipristal acetate)

one single oral dose (30 mg tablet)

Trial Locations (6)

CO 80218

PPRM Central clinic, Denver

CO 80232

PPRM Southwest clinic, Lakewood

PA 19107

Elizabeth Blackwell Health Center, Philadelphia

PA19107

Locust Health Center, Philadelphia

Unknown

Dept of Women & Child Health - Karolinska University Hospital, Stockholm

BT12DX

Brook clinic, Belfast

Sponsors

Lead Sponsor

HRA Pharma
All Listed Sponsors
lead

HRA Pharma

INDUSTRY

NCT01107106 - Safety, Tolerability, and Efficacy of ellaOne® (Ulipristal Acetate) for Emergency Contraception in Postmenarcheal Adolescent Girls and Women | Biotech Hunter | Biotech Hunter